Primas Bioscience Profile
Key Indicators
- Authorised Capital ₹ 6.50 M
as on 12-12-2024
- Paid Up Capital ₹ 1.85 M
as on 12-12-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.88 Cr
as on 12-12-2024
- Revenue 196.31%
(FY 2023)
- Profit -849.64%
(FY 2023)
- Ebitda -230.70%
(FY 2023)
- Net Worth 2049.49%
(FY 2023)
- Total Assets 1244.71%
(FY 2023)
About Primas Bioscience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.50 M and a paid-up capital of Rs 1.85 M.
The company currently has active open charges totaling ₹3.88 Cr.
Chandhrasekaran Kabilan, Dhanraj Muthu, Anju Chadha, and One other member serve as directors at the Company.
- CIN/LLPIN
U36999TN2019PTC129400
- Company No.
129400
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Primas Bioscience?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandhrasekaran Kabilan  | Managing Director | 22-May-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prabakaran | Additional Director | 19-Feb-2021 | Current |
| Dhanraj Muthu | Director | 22-May-2019 | Current |
| Anju Chadha | Additional Director | 19-Feb-2021 | Current |
Financial Performance of Primas Bioscience.
Primas Bioscience Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 196.31% increase. The company also saw a substantial fall in profitability, with a 849.64% decrease in profit. The company's net worth Soared by an impressive increase of 2049.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Primas Bioscience?
In 2023, Primas Bioscience had a public holding of 49.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jan 2024 | ₹5.00 M | Open |
Others Creation Date: 28 Feb 2023 | ₹3.38 Cr | Open |
How Many Employees Work at Primas Bioscience?
Primas Bioscience has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Primas Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Primas Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
